MoonLake Immunotherapeutics shares are trading higher after the company's Phase 2 study for Nanobody sonelokimabint met its primary endpoint in hidradenitis suppurativa.
Portfolio Pulse from Benzinga Newsdesk
MoonLake Immunotherapeutics' Phase 2 study for Nanobody sonelokimab met its primary endpoint in hidradenitis suppurativa, leading to higher trading of its shares.
June 26, 2023 | 12:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MoonLake Immunotherapeutics' successful Phase 2 study for Nanobody sonelokimab boosts its share prices.
The successful Phase 2 study for Nanobody sonelokimab in hidradenitis suppurativa indicates positive progress in MoonLake Immunotherapeutics' product pipeline, which is likely to boost investor confidence and lead to higher share prices in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100